Indivior Pharmaceuticals, Inc. (INDV)
32.45
-1.17
(-3.48%)
USD |
NASDAQ |
Oct 16, 16:00
32.41
-0.04
(-0.12%)
After-Hours: 20:00
Indivior Pharmaceuticals Research and Development Expense (Annual) : 80.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 80.00M |
| December 31, 2024 | 107.00M |
| December 31, 2023 | 116.00M |
| December 31, 2022 | 72.00M |
| December 31, 2021 | 52.00M |
| December 31, 2020 | 40.00M |
| December 31, 2019 | 53.00M |
| December 31, 2018 | 67.00M |
| Date | Value |
|---|---|
| December 31, 2017 | 89.00M |
| December 31, 2016 | 119.00M |
| December 31, 2015 | 148.00M |
| December 31, 2014 | 115.00M |
| December 31, 2013 | 76.00M |
| December 31, 2012 | 41.00M |
| December 31, 2011 | 35.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Supernus Pharmaceuticals, Inc. | 104.13M |
| Eli Lilly & Co. | 13.34B |
| Bristol Myers Squibb Co. | 9.492B |
| Liquidia Corp. | 38.45M |
| Harmony Biosciences Holdings, Inc. | 189.59M |